Acurx enrolls first patient in PATHFINDER Phase 2 trial of ibezapolstat

Acurx enrolled the first patient in PATHFINDER, a Phase 2 study of ibezapolstat in multiply recurrent C. difficile infection, with no results yet. The trial will assess clearing infection and reducing repeat episodes; management also reiterated plans for Phase 3 ASPIRE versus vancomycin subject to funding.